论文部分内容阅读
目的观察华法林改善非瓣膜性心房颤动患者血浆高凝状态指标。方法连续选择近期在我院心内科住院的非瓣膜性持续性心房颤动患者71例,后者接受了华法林抗凝治疗,初始口服剂量为1.25mg/d,根据INR进行调整,维持INR在2.0～3.0之间。治疗前和服药1个月后检测各种血凝指标。结果 71例非瓣膜性心房颤动患者经华法林抗凝治疗1个月后,血浆D-二聚体、纤维蛋白原、凝血酶原时间、部分凝血活酶时间和国际标准化比值均明显低于治疗前(P均<0.01～0.05)。结论口服华法林可显著改善非瓣膜性房颤患者血浆高凝状态指标。
Objective To observe the improvement of plasma hypercoagulability index of warfarin in patients with nonvalvular atrial fibrillation. Methods A total of 71 patients with non-valvular persistent atrial fibrillation who were hospitalized recently in our department of cardiology were enrolled. The latter received warfarin anticoagulation. The initial oral dose was 1.25 mg / d, adjusted according to INR and maintained at INR 2.0 ~ 3.0 between. Before treatment and medication after 1 month detection of various indicators of blood coagulation. Results After 71 months of warfarin anticoagulation therapy in 71 patients with non-valvular atrial fibrillation, the plasma D-dimer, fibrinogen, prothrombin time, partial thromboplastin time and the international normalized ratio were significantly lower than those before treatment (P <0.01 ~ 0.05). Conclusion oral warfarin can significantly improve the non-valvular atrial fibrillation plasma hypercoagulability indicators.